Chemeleon

Chemeleon pioneers ultra-rapid diagnostics with patented BINDS assays, delivering lab-precision results in <1 min from biological samples—no instruments/prep.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location New York, NY, USA
  • Currency USD
  • Founded September 2013
  • Employees 4
  • Incorporation Type C-corp
  • Website chemeleon.com

Company Summary

Chemeleon pioneers BINDS assays: patented, ultra-rapid, instrument-free diagnostics delivering lab-precision results in <$1 COGS. Modular for proteins/nucleic acids/small molecules. Partnerships: Mayo Clinic, US Army and MIT Lincoln Labs (chem-bio threats). 28 patents, 2025 ADLM Finalist.

Team

  • Brendan Walker (CEO), graduated the United States Military Academy with a BS and the Tuck School of Business at Dartmouth with a MBA. Brendan worked in investment banking, consulting, law and lead internal innovation at Danaher Corporation as Vice President of Science and Technology Innovation. He's a veteran entrepreneur with expertise in the full spectrum of startups, including finance, strategy, product development, sales, etc.

  • CTO

    Min Hu, PhD, graduated USTC with a BS and Notre Dame with a PhD in chemistry. He was a Philip Morris USA INEST research fellow at University of Washington and CREOL, College of Optics and Photonics at University of Central Florida and a member of the Central Nervous System for the Earth Project at HP Laboratories. His research includes nanostructured materials, chemical sensors, colloidal chemistry, self-assembly, surface modification, etc.

  • Principal Scientist

    Jacob Trevino graduated Susquehanna University with a BS and Boston University with a PhD in Materials Science and Engineering. He's a veteran researcher with expertise in developing nanostructured photonic systems for energy harvesting and sensing applications and nanostructured surfaces for enhanced biological interfaces. Prior to Chemeleon, he designed, fabricated and tested nano-photonic arrays for ultra-sensitive sensing of targets.

  • Mina Kang, PhD
    Research Scientist

    Mina heads up product research and development and is an expert biochemist. She holds a PhD and an MPhil in Biochemistry from The Graduate Center, City University of New York. At Seattle Children’s Research Institute, she studied myocardial protection for children with heart defects and collected clinical samples for AMI biomarker detection. During her PhD, she worked with siRNA using iron oxide nanocages to silence tumor-proliferation genes.

Previous Investors

  • Angel investor
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free